Literature DB >> 25574921

Serum drug concentrations of INH and RMP predict 2-month sputum culture results in tuberculosis patients.

A Mah1, H Kharrat2, R Ahmed1, Z Gao3, E Der4, E Hansen3, R Long1, D Kunimoto1, R Cooper1.   

Abstract

BACKGROUND: In Alberta provincial tuberculosis (TB) clinics, serum drug concentrations (SDCs) are measured in patients with human immunodeficiency virus, diabetes mellitus or at extremes of weight, or showing slow clinical response to treatment, to guide treatment.
DESIGN: A retrospective review was performed of TB cases in Northern Alberta with SDCs measured from 1998 to 2013. Adequacy of SDC was based on the maximum concentration (Cmax) achieved in serum, with rifampicin (RMP) values <8 μg/ml and isoniazid (INH) values <3 μg/ml for daily dosing and <9 μg/ml for intermittent dosing considered inadequate. Clinical variables and microbiological outcomes were then compared between the adequate and inadequate groups.
RESULTS: Of 134 pulmonary TB cases with SDCs for INH and/or RMP, we found a significant increase in 2-month sputum culture positivity in the cohort with inadequate concentrations of INH compared to those with adequate INH concentrations (42.5% vs. 18.3%, P = 0.0084). A similar trend was seen in the cohort with inadequate concentrations of RMP (39% vs. 21%, P = 0.0725).
CONCLUSIONS: Among our study population, low SDCs of INH and, to a lesser extent, RMP, appear to be associated with reduced sputum culture conversion after 2 months of treatment.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25574921     DOI: 10.5588/ijtld.14.0405

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  8 in total

1.  Evaluation of the Adequacy of the 2010 Revised World Health Organization Recommended Dosages of the First-line Antituberculosis Drugs for Children: Adequacy of Revised Dosages of TB Drugs for Children.

Authors:  Hongmei Yang; Anthony Enimil; Fizza S Gillani; Sampson Antwi; Albert Dompreh; Antoinette Ortsin; Eugene Adu Awhireng; Maxwell Owusu; Lubbe Wiesner; Charles A Peloquin; Awewura Kwara
Journal:  Pediatr Infect Dis J       Date:  2018-01       Impact factor: 2.129

2.  Delayed Sputum Culture Conversion in Tuberculosis-Human Immunodeficiency Virus-Coinfected Patients With Low Isoniazid and Rifampicin Concentrations.

Authors:  Christine Sekaggya-Wiltshire; Amrei von Braun; Mohammed Lamorde; Bruno Ledergerber; Allan Buzibye; Lars Henning; Joseph Musaazi; Ursula Gutteck; Paolo Denti; Miné de Kock; Alexander Jetter; Pauline Byakika-Kibwika; Nadia Eberhard; Joshua Matovu; Moses Joloba; Daniel Muller; Yukari C Manabe; Moses R Kamya; Natascia Corti; Andrew Kambugu; Barbara Castelnuovo; Jan S Fehr
Journal:  Clin Infect Dis       Date:  2018-08-16       Impact factor: 9.079

Review 3.  The utility of pharmacokinetic studies for the evaluation of exposure-response relationships for standard dose anti-tuberculosis drugs.

Authors:  Christine Sekaggya-Wiltshire; Mohammed Lamorde; Agnes N Kiragga; Kelly E Dooley; Moses R Kamya; Andrew Kambugu; Jan Fehr; Yukari C Manabe; Barbara Castelnuovo
Journal:  Tuberculosis (Edinb)       Date:  2017-11-07       Impact factor: 3.131

Review 4.  Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.

Authors:  Roger K Verbeeck; Gunar Günther; Dan Kibuule; Christian Hunter; Tim W Rennie
Journal:  Eur J Clin Pharmacol       Date:  2016-06-15       Impact factor: 2.953

5.  Effects of genetic variability on rifampicin and isoniazid pharmacokinetics in South African patients with recurrent tuberculosis.

Authors:  Anushka Naidoo; Maxwell Chirehwa; Veron Ramsuran; Helen McIlleron; Kogieleum Naidoo; Nonhlanhla Yende-Zuma; Ravesh Singh; Sinaye Ncgapu; John Adamson; Katya Govender; Paolo Denti; Nesri Padayatchi
Journal:  Pharmacogenomics       Date:  2019-02-15       Impact factor: 2.638

Review 6.  Recommendations for Optimizing Tuberculosis Treatment: Therapeutic Drug Monitoring, Pharmacogenetics, and Nutritional Status Considerations.

Authors:  Rihwa Choi; Byeong Ho Jeong; Won Jung Koh; Soo Youn Lee
Journal:  Ann Lab Med       Date:  2017-03       Impact factor: 3.464

Review 7.  The importance of clinical pharmacokinetic-pharmacodynamic studies in unraveling the determinants of early and late tuberculosis outcomes.

Authors:  Andrew D McCallum; Derek J Sloan
Journal:  Int J Pharmacokinet       Date:  2017-07-12

Review 8.  Current research toward optimizing dosing of first-line antituberculosis treatment.

Authors:  Helen McIlleron; Maxwell T Chirehwa
Journal:  Expert Rev Anti Infect Ther       Date:  2018-12-12       Impact factor: 5.091

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.